Add To Watchlist
Share URL
About The Company
Description
Zhejiang Wolwo Bio-Pharmaceutical Co.
Read More
Overview
Value
4
Growth
67
Health
73
Management
73
Analyst Opinion
80
Total
59
All Scores Out Of 100
Best Features
- Very strong cashflow and earnings growth
- Earnings growth has improved recently
- Has a low level of debt
- Low risk of bankruptcy
- Has strong financial health
- Liked by analysts
- Has strong dividend growth
- Low preportion of income is paid as dividend
Risk Factors
- Overvalued on cashflow basis
- No margin of safety at their current market price
- Price-to-earnings ratio of 64.9 is higher than the market average (19.6x)
Market Peers
300357.SZ
Key Figures
PE Ratio (TTM)
64.86
Margin Of Safety (DCF)
-80.14%
Revenue Growth (5 Year Average)
17.46%
Ratings Consensus
Buy
Share Buybacks
N/A
Dividend Yeild (TTM)
N/A
Valuation
Value Score
4
Desired Margin Of Safety
0%
▼
Tip: Set your desired Margin Of Safety
Free Cash Flow Type
Annual Cashflow Growth
0%
Discount Rate
0%
Buy Target: < 7.2 CNY ✘
Current Price: 56.3 CNY
How Does This Work?
Show Advanced Options
This calculator helps investors estimate the Intrinsic Value of a company based on the current value of future cash flows. To use the tool, simply input a desired Margin Of Safety, which is an additional discount applied to the present value of the expected future cash flows. The tool calculates the present value using a discount rate that reflects the risk and time value of money, and provides an estimated target price for the company based on the selected margin of safety. The calculator defaults to using 5 Year Free Cash Flow Growth % and a discount rate based on the US 10-year treasury bond coupon rate. Use our performance analyser to get a feel the impact this has on longterm investment returns and discover a margin of safety you are comfortable with. This can be a useful tool for investors looking to make informed decisions about whether to buy or sell shares of a particular company.
Price/Earnings
64.86x
Free Cashflow Yeild
0.60%
PE/Earnings Growth
3.03
Price/Book
14.66x
Growth
Growth Score
67
- ✔ 5 Year Average Revenue growth of 17.46% is higher than the market average (10.97%)
- ✔ Revenue growth has improved this yeara
- ✔ 5 Year Average Earnings growth of 16.95% is higher than the market average (14.48%)
- ✔ Earnings growth has improved this year
- ✔ 5 Year Average Cashflow growth of 18.79% is higher than the market average (12.35%)
- ✘ Free Cashflow growth has slowed this year
Revenue Growth
17.46%
Earnings Growth
16.95%
Cashflow Growth
18.79%
Health
Health Score
73
Altman Z Score
20.00
Piostroski Score
3.00
Debt/Equity
0.00x
Current Assets/Liabilities
12.42x
Free Cashflow/Total Debt
30.54x
Debt/Capital
0.01x
Dividend
Secure Dividend Score
55
- ✔ Dividend is likely safe
- ✔ Long term dividend payout ratio of 27.69% is considered good
- ✔ Payout ratio (TTM) of N/A is lower than the average (40%)
- ✔ Dividends have shown growth over the last 5 years
- ✔ Spending a lower percentage of their income on dividends than last 5 years
- ✘ Dividend yeild of N/A is less than the market average (1.85%)
- ✘ Dividend growth has been slowing recently
Dividend Yeild
N/A
Dividend Growth
-11.11%
Payout Ratio (Earnings)
N/A
Payout Ratio (Cashflow)
N/A
Management
Management Score
73
Average Buybacks/Dilution
N/A
Recent Buybacks/Dilution
-0.01%
5 Year Price Volitility
44.21%
Return On Assets
17.49%
Return On Capital Employed
22.31%
Return On Equity
19.47%
Return On Free Cashflow
181.64%
Return On Investments
405.49%
Analysts
Analyst Opinion
80
- ✔ Ratings consensus is Buy
SEC Filings
Find yearly (10-K), quaterly (10-Q) and disclosure (8-K) report here, on the Securities and Exchange Commission's EDGAR database. If reading through reports isn't your cup of tea, don't worry. We've made it easy for you by summarizing all the important bits.
Other Information
Company Name
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.
Currency
CNY
Beta
0.413987
Vol Avg
2383114
Ceo
Cik
Cusip
Exchange
Shenzhen
Full Time Employees
1488
Industry
Drug Manufacturers—General
Sector
Healthcare
Ipo Date
2014-01-21
Address
No. 636, Zhiyuan North Road
City
Huzhou
State
Country
CN
Zip
313200
Phone
86 57 2883 1088
All financial data provided by FMP